| 
| 
|  |  | Press Releases |  |  |  |  |  | 
|  |  | Friday, December 18, 2020 |  |  |  
| Hua Medicine Completes Registration Phase III Trials; Announces 52-Week Result for DAWN (HMM0302), Dorzagliatin's Phase III Combination with Metformin Trial |  | Hua Medicine (the "Company", Stock Code: 2552.HK), a leading innovative drug development company focused on developing novel therapies for the treatment of diabetes, today announced: more info >> |  |  |  | Wednesday, October 14, 2020 |  |  |  
| Hua Medicine Announces the Drug Manufacturing Permit Granted for Dorzagliatin |  | Hua Medicine (the "Company", Stock Code: 2552.HK) announces that, after review and on-site verification under the Marketing Authorization Holder ("MAH") system, the Company has obtained the drug manufacturing permit for dorzagliatin, its investigational first-in-class drug, issued by the Shanghai Municipal Drug Administrative Bureau. more info >>
 |  |  |  | Monday, August 17, 2020 |  |  |  
| Bayer and Hua Medicine announce commercialization agreement and strategic partnership for investigational first-in-class novel diabetes treatment dorzagliatin in China |  | Bayer and Hua Medicine, a leading innovative drug development company, today announced a commercialization agreement and strategic partnership for dorzagliatin, a novel diabetes treatment, in China. more info >> |  |  |  | Wednesday, July 1, 2020 |  |  |  
| Hua Medicine Announces Positive 24-Week Topline Results of Phase III Metformin Combination Trial of Dorzagliatin |  | Hua Medicine today announced the positive 24-week top-line results from HMM0302, a Phase III registration trial in China of its global first-in-class glucokinase activator dorzagliatin add-on to metformin, a first line oral antidiabetic therapy in Type 2 diabetes.   more info >> |  |  |  | Thursday, June 18, 2020 |  |  |  
| Hua Medicine Successfully Completes SEED (HMM0301), Dorzagliatin Phase III Monotherapy Trial |  | Hua Medicine (the "Company", Stock Code: 2552.HK), a leading innovative drug development company focused on developing novel therapies for the treatment of diabetes, today announced topline results from SEED (also known as HMM0301) more info >> |  |  |  | Monday, April 27, 2020 |  |  |  
| Hua Medicine Announces Positive Results in the Combination Study of Dorzagliatin with Empagliflozin (a SGLT-2 inhibitor) |  | Hua Medicine (the "Company", Stock Code: 2552. HK) today announces the positive results of the clinical study HMM0112. more info >> |  |  |  | Monday, March 16, 2020 |  |  |  
| Hua Medicine Announces 2019 Annual Results |  | Hua Medicine (the "Company", Stock Code on The Stock Exchange of Hong Kong Limited: 2552.HK), a global innovative drug research and development company focused on novel therapies for the treatment of diabetes, today announces the audited consolidated results of the Company and its subsidiaries for the year ended December 31, 2019.  more info >> |  |  |  | Friday, February 14, 2020 |  |  |  
| Hua Medicine appoints Dr. Fuxing Tang, a former U.S. FDA Officer, as Chief Technology Officer |  | Hua Medicine, a leading clinical stage biotechnology company based in Shanghai, is pleased to announce that Dr. Fuxing Tang has joined Hua Medicine as Chief Technology Officer, VP of Formulation R&D and Product Development.  more info >> |  |  |  |  |  |  |  |  |  |  |  | 
	|  |  | 
 
|  |  
| Latest Press Releases |  |  |  | 
| 
| Hitachi High-Tech Announces the SU9600: Next-Generation Ultrahigh-Resolution Scanning Electron Microscope with High Throughput Oct 31, 2025 0:45 JST
 |   |  |  |  
| Sharp to Introduce AQUOS sense10 Smartphone Oct 31, 2025 0:27 JST
 |   |  |  |  
| Fujitsu to provide digital ticketing service for NTT DOCOMO's new d ticket platform Oct 31, 2025 0:07 JST
 |   |  |  |  
| EESystem Triumphs Again: Courts Deem Jason Shurka's Claims "Baseless" and "Futile" Oct 31, 2025 21:45 HKT/SGT
 |   |  |  |  
| Autumn Lighting Fair, Outdoor and Tech Light Expo, Eco Expo Asia draw some 62,000 buyers Oct 31, 2025 19:56 HKT/SGT
 |   |  |  |  
| Saudi Arabia Assumes Chairmanship of INTOSAI Oct 31, 2025 19:45 HKT/SGT
 |   |  |  |  
| T-RIZE Strategically Collaborates with Republic and Canton to Launch the First New Construction Real Estate Equity Tokenization Deal on Canton Network, phase one of a $200M plan Oct 31, 2025 15:50 HKT/SGT
 |   |  |  |  
| IPO Watch - High-Margin International Business Scales Up Rapidly: Unpacking Hithium Energy Storage's Global Expansion Ambition Behind its Push for a Hong Kong Listing   Oct 31, 2025 15:20 HKT/SGT
 |  |  |  |  
| CIMC Group Announces the First Three Quarter Results for 2025 Oct 31, 2025 14:16 HKT/SGT
 |   |  |  |  
| Hong Kong delegation concludes mission in Riyadh Oct 31, 2025 11:19 HKT/SGT
 |   |  |  |  
| The Executive Centre Unveils New Premium Flexible Workspace at One IFC, Central Hong Kong   Oct 31, 2025 09:19 HKT/SGT
 |   |  |  |  
| Doubleview Gold Corp Announces Non-Brokered Private Placement of Flow-Through Shares at $1.00 per share along with Non-Flow-Through Units Oct 31, 2025 09:09 HKT/SGT
 |   |  |  |  
| HTD1801, a First-in-Class Anti-inflammatory Metabolic Modulator, Demonstrates Durable 52-Week Efficacy and Safety in Two Phase III Trials in Type 2 Diabetes Mellitus Oct 31, 2025 9:30 JST
 |   |  |  |  
| TruMerit's Peter Preziosi Elected President of the Conference of NGOs in Consultative Relationship With the United Nations Oct 31, 2025 04:00 HKT/SGT
 |   |  |  |  
| MHI and Nippon Shokubai to Develop Ammonia Cracking System for NEDO's "Development of Technologies for Building a Competitive Hydrogen Supply Chain" Project Oct 30, 2025 23:14 JST
 |   |  |  |  |  |  | More Press release >> |  |  |  |  |  
|  |  
|  |  |  |